Most sexual health medication works on blood flow. PT-141 works upstream—on the brain’s own desire and arousal pathways.
A peptide that approaches intimacy from the other direction.
PT-141 activates melanocortin receptors in the central nervous system—the desire side of intimacy, not just blood flow.
Unique mechanismBremelanotide is FDA-approved (as Vyleesi®) for low sexual desire in premenopausal women.
Providers prescribe PT-141 for both women and men when clinically appropriate.
Used shortly before intimacy—no daily regimen required.
For people whose challenge is wanting rather than performing, PT-141 offers a fundamentally different mechanism—one your provider can fit into a broader intimacy plan.
Get Started
“HDMeds has been a game changer. The process was simple, the care is incredible, and I've lost over 32 lbs in 4 months. I finally feel like myself again!”
“HDMeds helped me optimize my health and energy. I feel better than I have in years.”
“After a few weeks, my skin looks brighter and my hair feels stronger. I love that my plan is personalized and shipped discreetly to my door.”
“HDMeds made it easy to get the help I needed. Professional, discreet, and effective.”
“HDMeds has been a game changer. The process was simple, the care is incredible, and I've lost over 32 lbs in 4 months. I finally feel like myself again!”
“HDMeds helped me optimize my health and energy. I feel better than I have in years.”
“After a few weeks, my skin looks brighter and my hair feels stronger. I love that my plan is personalized and shipped discreetly to my door.”
“HDMeds made it easy to get the help I needed. Professional, discreet, and effective.”
PT-141 (bremelanotide) is a peptide that activates melanocortin receptors in the central nervous system, supporting sexual desire and arousal at the brain level rather than through blood flow.
Tadalafil and other PDE5 inhibitors work on blood flow; PT-141 works on desire signaling in the brain. They address different problems—and your provider will help identify which one matches yours.
Bremelanotide is FDA-approved as Vyleesi® for premenopausal women with hypoactive sexual desire disorder, and providers may prescribe PT-141 for other patients—including men—when clinically appropriate.
It's an as-needed treatment taken shortly before anticipated intimacy. Your provider gives exact timing and dosing guidance with your plan.
The most common are temporary nausea and facial flushing, particularly with early doses. Your provider will walk through what to expect and how to minimize it.
PT-141 with real provider guidance—private, personalized, delivered discreetly.
